Cardiol Therapeutics Confirms Involvement of Massachusetts General Hospital in Phase II MAvERIC-Pilot Study

Cardiol Therapeutics Inc. CRDL, a clinical-stage biotechnology company specialized in the development of novel anti-inflammatory therapies for cardiovascular diseases (CVD), has announced an exciting milestone in their MAvERIC-Pilot study. The Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School, has recently joined as the 8th major medical centre participating in this important clinical trial.

Advancing Cardiovascular Research

The Phase II study, known as MAvERIC-Pilot, is designed to focus on patients with recurrent pericarditis, a condition characterized by the inflammation of the pericardium, the fibrous sac surrounding the heart. This progressive trial aims to address this debilitating condition that poses a significant challenge to the medical community.

A Major Step for Cardiol Therapeutics

Teaming up with such a prestigious institution as Massachusetts General Hospital signifies a major step forward for Cardiol Therapeutics and their groundbreaking research. The partnership further underscores the therapeutic potential of the company's products and their commitment to addressing unmet medical needs within the sphere of cardiovascular health.

Anticipated Completion of Patient Recruitment

The MAvERIC-Pilot study is on a promising trajectory, with expectations to complete patient recruitment by the first quarter of 2024. This timeline reflects Cardiol's dedication to progressing their research and development efforts promptly and efficiently, bringing them closer to potentially offering new relief options to individuals suffering from recurrent pericarditis.

Cardiol Therapeutics at a Glance

With headquarters in Oakville, Canada, Cardiol Therapeutics is at the forefront of anti-inflammatory therapy for CVD. As the company continues to expand the scope of their clinical studies through collaborations with top-tier medical centers, they further reinforce their position within the biotechnology landscape.

Cardiol, MAvERIC-Pilot, Pericarditis